| Not Yet Recruiting | Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study NCT07412041 | Dana-Farber Cancer Institute | N/A |
| Not Yet Recruiting | Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer NCT06552000 | University of Texas Southwestern Medical Center | N/A |
| Not Yet Recruiting | Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s) NCT06502249 | Ain Shams University | — |
| Not Yet Recruiting | Post-Market Registry of Transbronchial Cryo-assisted RFA During Routine Standard Bronchoscopic Tumor Stagng an NCT07530744 | Elisabethinen Hospital | N/A |
| Not Yet Recruiting | Clinical Effectiveness and Safety of SHR-A1811 in Chinese Patients With HER2-Altered NSCLC NCT07516015 | Nanjing Tianyinshan Hospital | — |
| Not Yet Recruiting | Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Can NCT07379398 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Not Yet Recruiting | Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases NCT07413952 | The First Affiliated Hospital of Guangzhou Medical University | Phase 2 |
| Not Yet Recruiting | A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metas NCT07376382 | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 3 |
| Not Yet Recruiting | Clinical Trial of TB511 in Advanced Solid Tumors NCT06400160 | Twinpig Biolab, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC NCT07158489 | Swiss Cancer Institute | Phase 2 |
| Recruiting | Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC NCT07479277 | Fondazione del Piemonte per l'Oncologia | N/A |
| Not Yet Recruiting | Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer NCT05909137 | Xinqiao Hospital of Chongqing | — |
| Recruiting | Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors NCT07397338 | Revolution Medicines, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperat NCT07358689 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors NCT07349537 | Revolution Medicines, Inc. | Phase 1 |
| Not Yet Recruiting | Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk Factors NCT07330076 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial L NCT07323732 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors NCT07274813 | Shanghai Henlius Biotech | EARLY_Phase 1 |
| Not Yet Recruiting | Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadju NCT07286942 | Jiangsu Cancer Institute & Hospital | Phase 2 |
| Recruiting | Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site NCT07325864 | European Institute of Oncology | — |
| Recruiting | HC010 in First-line PD-L1 Positive Advanced NSCLC Patients NCT07169552 | HC Biopharma Inc. | Phase 2 |
| Not Yet Recruiting | Influence of a PSychological Intensive Support Program for Lung Cancer Patients ON Post-operative Outcomes. NCT07260227 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Recruiting | Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer（NSCLC） NCT07388771 | Qian Chu | — |
| Not Yet Recruiting | A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small C NCT07281209 | Shanghai Chest Hospital | Phase 2 |
| Recruiting | TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadju NCT07330037 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Not Yet Recruiting | Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC NCT07231575 | Sun Yat-sen University | Phase 2 |
| Recruiting | A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors NCT07182149 | Normunity AccelCo, Inc. | Phase 1 |
| Recruiting | Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Can NCT06671613 | VA Office of Research and Development | N/A |
| Not Yet Recruiting | Vebreltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC) NCT07156604 | Fudan University | Phase 2 |
| Not Yet Recruiting | A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced NCT07198321 | Genfleet Therapeutics (Shanghai) Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung C NCT07153770 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 |
| Not Yet Recruiting | Analysis of Deoxyribonucleic Acid and Ribonucleic Acid Next-Generation Sequencing in Non-Small Cell Lung Cance NCT07179445 | Tianjin Medical University Cancer Institute and Hospital | — |
| Recruiting | A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable N NCT07082179 | Jiangsu Cancer Institute & Hospital | Phase 2 |
| Recruiting | Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Th NCT07181499 | Betta Pharmaceuticals Co., Ltd. | Phase 2 |
| Enrolling By Invitation | A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Product NCT06885424 | A2 Biotherapeutics Inc. | — |
| Recruiting | The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the NCT07138755 | The Third Xiangya Hospital of Central South University | Phase 2 |
| Recruiting | Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer NCT06865339 | Montefiore Medical Center | Phase 2 |
| Not Yet Recruiting | QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC NCT07134413 | Guangdong Association of Clinical Trials | Phase 2 |
| Not Yet Recruiting | A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC NCT07086326 | Yang Fan, MD | Phase 2 |
| Not Yet Recruiting | Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer(TitAN) : NCT07089199 | Qilu Hospital of Shandong University | Phase 2 |
| Recruiting | REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis NCT06315010 | MedSIR | Phase 2 |
| Not Yet Recruiting | Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC NCT07035392 | Zhangzhou Municipal Hospital | Phase 2 |
| Recruiting | Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (N NCT06620835 | Groupe Francais De Pneumo-Cancerologie | Phase 2 |
| Not Yet Recruiting | A Study of DCTY1102 Injection in Patients With Advanced Solid Tumors NCT07014878 | Beijing DCTY Biotech Co.,Ltd. | Phase 1 |
| Recruiting | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients NCT06922591 | Tango Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participan NCT07010419 | Allist Pharmaceuticals, Inc. | Phase 3 |
| Recruiting | SLV-154 Treatment of Metastatic Solid Tumors NCT06771219 | Solve Therapeutics | Phase 1 |
| Not Yet Recruiting | Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction T NCT06893354 | The First Affiliated Hospital of Guangzhou Medical University | Phase 4 |
| Recruiting | Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) NCT06881784 | Revolution Medicines, Inc. | Phase 3 |
| Recruiting | PET/CT for Trop2 ADC Response Evaluation NSCLC NCT07151898 | The First Affiliated Hospital of Xiamen University | — |
| Recruiting | JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations NCT06940401 | Suzhou Junjing BioSciences Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors NCT06816108 | Ono Pharmaceutical Co., Ltd. | Phase 1 |
| Not Yet Recruiting | JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC NCT06944470 | Shanghai Junshi Bioscience Co., Ltd. | Phase 2 |
| Recruiting | A Randomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintenance Therapy in ctDNA Positive NSC NCT07264673 | Fondazione Ricerca Traslazionale | Phase 2 |
| Recruiting | Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal M NCT07092202 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 4 |
| Recruiting | OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction NCT06462963 | European Organisation for Research and Treatment of Cancer - EORTC | N/A |
| Recruiting | Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD NCT06924710 | Peking University Cancer Hospital & Institute | N/A |
| Recruiting | A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR NCT06945705 | Henan Cancer Hospital | Phase 2 |
| Recruiting | BBO-11818 in Adult Subjects With KRAS Mutant Cancer NCT06917079 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Phase 1 |
| Not Yet Recruiting | The Efficacy and Safety of Ensartinib As Adjuvant Therapy in Stage I ALK-positive NSCLC Patients with High Ris NCT06772610 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 |
| Recruiting | A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC NCT06844474 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 2 |
| Recruiting | ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC NCT06816992 | ORIC Pharmaceuticals | Phase 1 |
| Recruiting | Validation of the TheraSure CNI-Monitor Under Immuno-checkpoint-therapy (Hereinafter: "Immunotherapy") in NSCL NCT05426668 | Karsten Gavenis | — |
| Recruiting | The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung C NCT05798845 | Shanghai Chest Hospital | Phase 2 |
| Not Yet Recruiting | A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Re NCT06672068 | TYK Medicines, Inc | Phase 2 |
| Recruiting | Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC NCT06864624 | Tang-Du Hospital | Phase 2 |
| Recruiting | The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the NCT06738160 | Fudan University | Phase 2 |
| Recruiting | Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer NCT06731413 | Virginia Commonwealth University | Phase 2 |
| Not Yet Recruiting | Immuno-pet IMaging ResPonses AdministeRed Immune CheckpoiNt InhibiTor NCT06218069 | Radboud University Medical Center | Phase 2 / Phase 3 |
| Recruiting | A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors NCT06789172 | Epkin | Phase 1 |
| Recruiting | A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With I NCT06754644 | Qilu Pharmaceutical Co., Ltd. | Phase 3 |
| Not Yet Recruiting | MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer NCT06735508 | Guangdong Provincial People's Hospital | EARLY_Phase 1 |
| Not Yet Recruiting | Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs NCT06766591 | Jiangsu Province Nanjing Brain Hospital | N/A |
| Not Yet Recruiting | A Multicenter Real-world Clinical Study on the Efficacy and Safety of Ensartinib As Neoadjuvant Treatment for NCT06736561 | Harbin Medical University | — |
| Not Yet Recruiting | Clinical Trial to Evaluate the Efficacy and Safety of Pulsed Electric Field Ablation Devices in the Treatment NCT06739031 | Energenx Medical LTD. | N/A |
| Recruiting | LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients NCT06576635 | University of Illinois at Chicago | N/A |
| Recruiting | First in Human Study of TUB-030 in Patients With Advanced Solid Tumors NCT06657222 | Tubulis GmbH | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lu NCT06685718 | BeOne Medicines | Phase 1 |
| Recruiting | Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Resp NCT06457789 | Amsterdam UMC, location VUmc | N/A |
| Not Yet Recruiting | Post-Market Surveillance Study of ALK-Positive Advanced NSCLC Participants Treated With Iruplinalkib NCT06644495 | Qilu Pharmaceutical Co., Ltd. | — |
| Not Yet Recruiting | A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 NCT06746870 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Phase 2 |
| Recruiting | Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC NCT06714708 | Anhui Provincial Cancer Hospital | Phase 2 |
| Not Yet Recruiting | A Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemothe NCT06684873 | Sun Yat-sen University | Phase 2 |
| Enrolling By Invitation | Perioperative Treatment Outcomes of Early NSCLC NCT06610240 | Shanghai Chest Hospital | — |
| Not Yet Recruiting | The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-pos NCT06652555 | Shanghai Pulmonary Hospital, Shanghai, China | — |
| Active Not Recruiting | A Prospective Observational Study of Changes in Cortisol Levels After Neoadjuvant Immunotherapy and Their Prog NCT07530276 | Guangdong Provincial People's Hospital | — |
| Recruiting | Nintedanib for the Prevention of Radiation Pneumonia in Unresectable NSCLC NCT06570317 | Second Hospital of Shanxi Medical University | — |
| Recruiting | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369 | 7 Hills Pharma, LLC | Phase 1 / Phase 2 |
| Recruiting | Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases NCT06248606 | Ryan Gentzler, MD | Phase 2 |
| Recruiting | Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC NCT06532591 | Sichuan Cancer Hospital and Research Institute | Phase 2 |
| Not Yet Recruiting | SHR-A1921 Combined With Adebrelimab in the Treatment of Advanced NSCLC Who Failed the Previous Standard First- NCT06480136 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 |
| Recruiting | Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study NCT06534762 | Zhejiang Provincial People's Hospital | Phase 2 |
| Not Yet Recruiting | The Clinical Characteristics and Efficacy of Immunotherapy in First-line PD-L1-negative Advanced NSCLC Patient NCT06496009 | Shanghai Pulmonary Hospital, Shanghai, China | — |
| Active Not Recruiting | Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage II NCT06448910 | Fudan University | Phase 2 |
| Recruiting | A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Adva NCT06467383 | MSD Italia S.r.l. | — |
| Recruiting | Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous No NCT06422143 | Merck Sharp & Dohme LLC | Phase 3 |
| Recruiting | Transcriptional Framework for the Molecular Diagnosis of Response to Immunotherapy in Lung Cancer With Agnosti NCT06807307 | Regina Elena Cancer Institute | — |
| Not Yet Recruiting | Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC NCT06465238 | Henan Cancer Hospital | Phase 2 |
| Not Yet Recruiting | Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation NCT06414915 | National Cancer Center, China | Phase 2 |
| Not Yet Recruiting | Distributed Learning of Edic and CardIac Dose Effects in Lung Cancer NCT06329648 | The Netherlands Cancer Institute | — |
| Recruiting | Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer NCT06343402 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Phase 1 |
| Recruiting | A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations NCT06362980 | National Cancer Center, China | Phase 1 |
| Recruiting | A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients NCT06361927 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 2 |
| Recruiting | Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lun NCT06431685 | Sichuan University | Phase 1 |
| Recruiting | A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors NCT06326411 | Nested Therapeutics, Inc | Phase 1 |
| Recruiting | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With So NCT06051695 | A2 Biotherapeutics Inc. | Phase 1 / Phase 2 |
| Recruiting | Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations NCT06062823 | National University Hospital, Singapore | Phase 2 |
| Recruiting | Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK) NCT06221670 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Completed | Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Hea NCT06255951 | TYK Medicines, Inc | Phase 1 |
| Recruiting | Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally S NCT05987644 | Joshua Palmer | Phase 1 / Phase 2 |
| Recruiting | Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy NCT06317558 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | — |
| Unknown | A Study Developing a Non-invasive Urine-based Proteomic Model for Early Lung Cancer Detection. NCT06733311 | Beijing Chao Yang Hospital | — |
| Recruiting | A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC NCT06246110 | Eikon Therapeutics | Phase 2 |
| Not Yet Recruiting | Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations NCT06054191 | Sun Yat-sen University | Phase 2 |
| Completed | The Food-effect on Alectinib Pharmacokinetics NCT05710133 | The Netherlands Cancer Institute | N/A |
| Withdrawn | An Exploratory Clinical Study of Adebelimumab in Combination With Famitinib and Chemotherapy in Patients With NCT06332300 | Jiangsu Province Nanjing Brain Hospital | Phase 2 |
| Recruiting | Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Sing NCT07085182 | Zibo Municipal Hospital | Phase 2 |
| Recruiting | LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer NCT06479759 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 |
| Not Yet Recruiting | A Study of Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer NCT06182761 | Shanghai Zhongshan Hospital | Phase 2 |
| Unknown | A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis NCT06339242 | Jiangsu Province Nanjing Brain Hospital | Phase 2 |
| Recruiting | A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer NCT05991193 | Hunan Province Tumor Hospital | — |
| Recruiting | A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet Chemotherapy as Neoadjuvant Ther NCT05991206 | Hunan Province Tumor Hospital | — |
| Recruiting | A Study of YL202 in Selected Patients With Advanced Solid Tumors NCT06107686 | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 2 |
| Active Not Recruiting | Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC NCT05798663 | Alliance Foundation Trials, LLC. | Phase 2 |
| Terminated | A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV NCT06094296 | Bristol-Myers Squibb | Phase 2 |
| Unknown | Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations NCT06029816 | Convalife (Shanghai) Co., Ltd. | Phase 2 |
| Recruiting | RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC NCT06142058 | Xueqin Yang | — |
| Active Not Recruiting | A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Adva NCT06403436 | TOLREMO therapeutics AG | Phase 1 |
| Not Yet Recruiting | Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib NCT05988697 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | — |
| Recruiting | Study on c-Met Targeted PET/CT Imaging in NSCLC NCT06911697 | Xilin Sun | N/A |
| Unknown | A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung Cancer NCT06108726 | Northern Jiangsu People's Hospital | Phase 2 |
| Recruiting | Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS) NCT06116019 | Charite University, Berlin, Germany | — |
| Recruiting | Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC NCT07247227 | Peking Union Medical College | N/A |
| Recruiting | First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lun NCT06043817 | Pierre Fabre Medicament | Phase 1 / Phase 2 |
| Active Not Recruiting | Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer NCT05714891 | Canadian Cancer Trials Group | Phase 2 |
| Recruiting | 99mTc-H7ND SPECT/CT Imaging in NSCLC NCT05999214 | First Affiliated Hospital Xi'an Jiaotong University | N/A |
| Recruiting | Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types NCT05877430 | CJ Bioscience, Inc. | Phase 1 / Phase 2 |
| Recruiting | RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC NCT05821933 | RemeGen Co., Ltd. | Phase 1 / Phase 2 |
| Withdrawn | EGFR_IUO 3.20 Clinical Study Protocol NCT05959473 | Biocartis NV | N/A |
| Unknown | The Efficacy and Safety of KN046 Combined With Axitinib NCT06020352 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 / Phase 3 |
| Recruiting | TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases NCT05948813 | TYK Medicines, Inc | Phase 2 |
| Unknown | A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC NCT06328049 | Taixing People's Hospital | Phase 2 |
| Terminated | Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Can NCT05840510 | Mirati Therapeutics Inc. | Phase 1 |
| Recruiting | Compare the Prognostic Differences Between SBRT and Surgery for NSCLC Patients With Interlobular Fissure Invas NCT06317324 | Tianjin Medical University Cancer Institute and Hospital | — |
| Active Not Recruiting | A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC NCT05773092 | National Cancer Centre, Singapore | Phase 2 |
| Terminated | BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations NCT06032936 | LianBio LLC | Phase 1 |
| Recruiting | A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue NCT05837767 | Memorial Sloan Kettering Cancer Center | N/A |
| Recruiting | IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC NCT05994131 | InxMed (Shanghai) Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunother NCT05703269 | Wake Forest University Health Sciences | N/A |
| Recruiting | Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung Cancer NCT05987345 | Energenx Medical LTD. | N/A |
| Recruiting | Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC NCT06424821 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 |
| Completed | Study on Food Influence and Drug-drug Interaction of HLX208 Tablets in Chinese Healthy Subjects NCT05902728 | Shanghai Henlius Biotech | Phase 1 |
| Unknown | Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell NCT05932264 | Sun Yat-sen University | Phase 2 |
| Recruiting | Safety and Efficacy of NK510 to Treat NSCLC NCT06097962 | Base Therapeutics (Shanghai) Co., Ltd. | EARLY_Phase 1 |
| Active Not Recruiting | A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC NCT05756972 | Biotheus Inc. | Phase 2 |
| Recruiting | Study of LP-184 in Patients With Advanced Solid Tumors NCT05933265 | Lantern Pharma Inc. | Phase 1 / Phase 2 |
| Withdrawn | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss NCT06090318 | Rain Oncology Inc | Phase 1 / Phase 2 |
| Terminated | A Biomarker Screening Protocol for Participants With Solid Tumors NCT05891197 | Lyell Immunopharma, Inc. | — |
| Active Not Recruiting | Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer NCT05882513 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Recruiting | DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors NCT05684276 | Fundación GECP | Phase 2 |
| Unknown | A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced NSCLC With Leptomeningeal Metas NCT06332287 | Jiangsu Province Nanjing Brain Hospital | Phase 2 |
| Active Not Recruiting | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors NCT05736731 | A2 Biotherapeutics Inc. | Phase 1 / Phase 2 |
| Recruiting | Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies NCT05786924 | Institut de Recherches Internationales Servier | Phase 1 / Phase 2 |
| Recruiting | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors NCT05787587 | IDEAYA Biosciences | Phase 1 |
| Recruiting | Prospective Evaluation of Single Cell Mutations in a Panel of Known Oncogenes in NSCLC Surgical Specimens NCT06050278 | University of Milano Bicocca | — |
| Not Yet Recruiting | Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR NCT05778149 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation NCT06050980 | Haisco Pharmaceutical Group Co., Ltd. | Phase 1 |
| Recruiting | A Study of XZB-0004 in Patients With Solid Tumors NCT05772455 | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 1 |
| Terminated | Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer NCT05652868 | Mythic Therapeutics | Phase 1 |
| Unknown | Milciclib in Combination With Gemcitabine in Advanced NSCLC NCT05651269 | Tiziana Life Sciences LTD | Phase 2 |
| Recruiting | A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies NCT05753722 | Incendia Therapeutics | Phase 1 |
| Unknown | A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metasta NCT05741021 | Shandong New Time Pharmaceutical Co., LTD | Phase 2 |
| Terminated | Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients NCT05636267 | Akeso | Phase 1 / Phase 2 |
| Unknown | Folinic Acid for Prevention of Pemetrexed-induced Toxicity NCT06010277 | Amphia Hospital | Phase 4 |
| Withdrawn | Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer NCT05693090 | Kura Oncology, Inc. | Phase 1 |
| Terminated | Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC NCT05583188 | Galvanize Therapeutics, Inc. | Phase 4 |
| Terminated | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancr NCT05631574 | Biomea Fusion Inc. | Phase 1 |
| Active Not Recruiting | Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients NCT05463224 | Se-Hoon Lee | Phase 2 |
| Active Not Recruiting | Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advance NCT05687266 | AstraZeneca | Phase 3 |
| Recruiting | Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tu NCT05283330 | Orano Med LLC | Phase 1 |
| Unknown | Almonertinib Plus Metronomic Oral Vinorelbine NCT05663177 | Fujian Cancer Hospital | — |
| Terminated | Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Rec NCT05493501 | EQRx International, Inc. | Phase 3 |
| Recruiting | A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) NCT05657873 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combi NCT05668585 | C4 Therapeutics, Inc. | Phase 1 |
| Terminated | Oral AMXT 1501 Dicaprate in Combination With IV DFMO NCT05500508 | Aminex Therapeutics, Inc. | Phase 1 / Phase 2 |
| Unknown | Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung Cancer NCT06081777 | Peking University Cancer Hospital & Institute | — |
| Unknown | SBRT Versus Conventional Fractionated Radiotherapy for Vertebral Metastases NCT05577052 | Wuhan University | N/A |
| Unknown | PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial NCT05605613 | Xuhua Duan | Phase 2 / Phase 3 |
| Recruiting | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combinat NCT05581004 | Genentech, Inc. | Phase 1 |
| Active Not Recruiting | Study of Oral MRT-2359 in Selected Cancer Patients NCT05546268 | Monte Rosa Therapeutics, Inc | Phase 1 / Phase 2 |
| Recruiting | APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innov NCT05550961 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | — |
| Recruiting | A Study of EP0031 in Patients With Advanced RET-altered Malignancies NCT05443126 | Ellipses Pharma | Phase 1 / Phase 2 |
| Unknown | The Dynamic Monitoring of Cerebrospinal Fluid ctDNA NCT06315686 | Jiangsu Province Nanjing Brain Hospital | Phase 2 |
| Active Not Recruiting | Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 I NCT05466149 | Allist Pharmaceuticals, Inc. | Phase 2 |
| Unknown | Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Canc NCT05547737 | Henan Cancer Hospital | — |
| Unknown | Efficacy and Safety of Microwave Ablation Combined With Camrelizumab and Chemotherapy in Patients With Advance NCT05532527 | Henan Provincial People's Hospital | N/A |
| Terminated | A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer NCT05492045 | InventisBio Co., Ltd | Phase 1 / Phase 2 |
| Recruiting | A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma NCT05341557 | Betta Pharmaceuticals Co., Ltd. | Phase 1 |
| Recruiting | A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors NCT05417321 | Shanghai Huaota Biopharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Phase 1/2 Study of BA3071 in Patients With Solid Tumors NCT05180799 | BioAtla, Inc. | Phase 1 / Phase 2 |
| Recruiting | Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC NCT05332925 | Jun Zhang, MD, PhD | — |
| Completed | Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE) NCT05465343 | Peking Union Medical College | Phase 2 |
| Completed | Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1 NCT05383482 | Laekna Limited | Phase 1 / Phase 2 |
| Unknown | Penpulimab Combined With Anlotinib in Neoadjuvant Treatment of Resectable Non-small Cell Lung Cancer NCT05387109 | Tang-Du Hospital | Phase 4 |
| Active Not Recruiting | Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR Mutation NCT06247280 | Yuhan Corporation | — |
| Recruiting | MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC NCT05286957 | The First Affiliated Hospital of Zhengzhou University | Phase 2 |
| Recruiting | Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers NCT04712877 | Lung Cancer Mutation Consortium | — |
| Completed | A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) NCT05429320 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO) NCT05382728 | TYK Medicines, Inc | Phase 3 |
| Unknown | A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor NCT05332574 | Genor Biopharma Co., Ltd. | Phase 1 / Phase 2 |
| Suspended | A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring H NCT05378763 | Spectrum Pharmaceuticals, Inc | Phase 3 |
| Completed | Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation NCT05146219 | TYK Medicines, Inc | Phase 2 |
| Unknown | ERK Inhibitor JSI-1187 in Advanced Solid Tumors NCT06239623 | JS InnoPharm, LLC | Phase 1 |
| Unknown | Lazertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations NCT05277701 | Yonsei University | Phase 2 |
| Active Not Recruiting | Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With E NCT05256290 | Black Diamond Therapeutics, Inc. | Phase 1 / Phase 2 |
| Terminated | A Study to Investigate LYL797 in Adults With Solid Tumors NCT05274451 | Lyell Immunopharma, Inc. | Phase 1 |
| Completed | Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium NCT05273827 | Tianjin Medical University Cancer Institute and Hospital | — |
| Recruiting | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy NCT05621837 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | — |
| Unknown | Efficacy and Safety of Neoantigen Peptide Vaccine in the Treatment of Advanced NSCLC Progressed After EGFR-TKI NCT06095934 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | N/A |
| Unknown | Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC NCT05209256 | The First Affiliated Hospital of Henan University of Science and Technology | Phase 2 / Phase 3 |
| Unknown | RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC NCT05273047 | Intergroupe Francophone de Cancerologie Thoracique | — |
| Recruiting | The CyberChallenge Trial How Much is Too Much - What is the Role of Cyberknife Radiosurgery in Patients With M NCT05378633 | University Hospital Heidelberg | N/A |
| Unknown | Study of HA121-28 in Patients With Non-Small Cell Lung Cancer NCT05117658 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 2 |
| Active Not Recruiting | Residual Disease Evaluation of Resected NSCLC by cirDNA Analysis NCT05165160 | University Hospital, Montpellier | N/A |
| Recruiting | Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients NCT04772235 | Instituto Oncológico Dr Rosell | Phase 1 |
| Completed | Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) NCT05259696 | Palleon Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study NCT05089916 | AIO-Studien-gGmbH | Phase 2 |
| Recruiting | PRIME_LUNG: Primary Radiotherapy In MEtastatic Lung Cancer - A Pilot Study NCT05222087 | Peter MacCallum Cancer Centre, Australia | Phase 1 |
| Not Yet Recruiting | Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Aden NCT05132985 | Liaoning Cancer Hospital & Institute | Phase 2 |
| Unknown | Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Ca NCT05165355 | Tongji University | Phase 2 |
| Active Not Recruiting | Lorlatinib Continuation Study NCT05144997 | Pfizer | Phase 4 |
| Active Not Recruiting | Crizotinib Continuation Clinical Study NCT05160922 | Pfizer | Phase 4 |
| Terminated | Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants NCT04939701 | Astellas Pharma Global Development, Inc. | Phase 1 / Phase 2 |
| Recruiting | Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC. NCT05615142 | Sichuan University | Phase 1 |
| Completed | Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab NCT05061017 | Diwakar Davar | Phase 2 |
| Completed | QYJD Compound Preparation Promotes Rapid Postoperative Recovery in Early-stage NSCLC Patients by Regulating Ti NCT06766565 | Fuzhou General Hospital | Phase 1 |
| Unknown | Clinical Trial of GAIA-102 for Advanced and Relapse NSCLC NCT05207371 | GAIA BioMedicine Inc. | Phase 1 / Phase 2 |
| Completed | Tislelizumab in Addition to BACE in Patients with NSCLC NCT05058560 | The First Affiliated Hospital of Zhengzhou University | Phase 2 |
| Recruiting | First in Human Study of TORL-1-23 in Participants With Advanced Cancer NCT05103683 | TORL Biotherapeutics, LLC | Phase 1 |
| Unknown | A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 Mu NCT05065398 | Shanghai Henlius Biotech | Phase 2 |
| Withdrawn | Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC NCT05007769 | Washington University School of Medicine | Phase 2 |
| Active Not Recruiting | A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors NCT05117476 | Cullinan Therapeutics Inc. | Phase 1 |
| Recruiting | Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing NCT04981119 | A2 Biotherapeutics Inc. | — |
| Active Not Recruiting | A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients NCT05078931 | Shanghai Chest Hospital | Phase 2 |
| Unknown | Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC NCT04989322 | Dr Joanne CHIU | Phase 2 |
| Completed | Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negati NCT05021328 | Hubei Cancer Hospital | Phase 1 |
| Withdrawn | Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation NCT04958967 | Allist Pharmaceuticals, Inc. | Phase 1 |
| Withdrawn | Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With Pembrolizumab NCT04677361 | Fox Chase Cancer Center | EARLY_Phase 1 |
| Active Not Recruiting | Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are NCT05059522 | Pfizer | Phase 3 |
| Completed | JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation NCT05002270 | Jacobio Pharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC. NCT05005468 | Shanghai Chest Hospital | Phase 2 |
| Completed | AI-EBUS-Elastography for LN Staging NCT04816981 | St. Joseph's Healthcare Hamilton | N/A |
| Terminated | Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer NCT04822298 | Amgen | Phase 1 |
| Recruiting | Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NCT04585490 | Maximilian Diehn | Phase 3 |
| Unknown | Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Soli NCT04780217 | ImmVira Pharma Co. Ltd | Phase 1 / Phase 2 |
| Unknown | JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety NCT04874844 | Beijing Dongfang Biotech Co., Ltd. | Phase 2 / Phase 3 |
| Terminated | A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NCT04849273 | Turning Point Therapeutics, Inc. | Phase 1 |
| Active Not Recruiting | A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China NCT05009329 | Allist Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Unknown | Uniportal Tubeless VATS for the Evaluation of Biopsy for Second-generation Sequencing in Patients With Advance NCT04950907 | Jianxing He | N/A |
| Unknown | Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis NCT04944069 | Second Affiliated Hospital of Nanchang University | N/A |
| Completed | To Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Different Racial and Ethnic Popul NCT04969965 | EQRx, Inc. | Phase 1 |
| Active Not Recruiting | A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer NCT04746924 | BeiGene | Phase 3 |
| Unknown | 18F-FDG PET/CT to Evaluate pD-1 Monoclonal Antibody With First-line Chemotherapy in Advanced NSCLC NCT04996927 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | — |
| Completed | An Observational Study to Evaluate the Clinical Utility of the Oncomine Precision Assay Within the Exactis Net NCT04564079 | Exactis Innovation | — |
| Unknown | Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases NCT04870190 | Shanghai Chest Hospital | Phase 3 |
| Recruiting | CPAP or BiPAP for Motion Mitigation During Radiotherapy NCT04986293 | University Medical Center Groningen | N/A |
| Completed | A Trial Evaluating Stereotactic Radiotherapy Plus Durvalumab Continuation for Patients With NSCLC Metachronous NCT03955198 | Institut Claudius Regaud | Phase 2 |
| Recruiting | Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy. NCT04720339 | University Hospital, Strasbourg, France | N/A |
| Recruiting | Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Com NCT07198217 | Zibo Municipal Hospital | Phase 2 |
| Recruiting | Study Investigating Anti-drug Antibodies in NSCLC Patients Exposed to Checkpoint Inhibitors (IMB) NCT06823401 | Fondazione Ricerca Traslazionale | — |
| Active Not Recruiting | An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NS NCT04764188 | Hoffmann-La Roche | — |
| Recruiting | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors NCT04686682 | Jacobio Pharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients NCT03866499 | Beta Pharma Shanghai | Phase 3 |
| Recruiting | Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiothe NCT04892849 | University of Erlangen-Nürnberg Medical School | — |
| Terminated | Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (N NCT04863248 | G1 Therapeutics, Inc. | Phase 2 |
| Terminated | Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment NCT04820023 | Bridge Biotherapeutics, Inc. | Phase 1 / Phase 2 |
| Unknown | High Throughput Screening Device Based on 3D Nano-matrices and 3D Tumors With Functional Vascularization NCT04826913 | University Hospital, Strasbourg, France | — |
| Recruiting | Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors NCT04665206 | Vivace Therapeutics, Inc | Phase 1 / Phase 2 |
| Completed | JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors NCT04720976 | Allist Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Unknown | A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTIST NCT04778800 | Henan Cancer Hospital | N/A |
| Completed | Study to Evaluate D-1553 in Subjects With Lung Cancer NCT05383898 | InventisBio Co., Ltd | Phase 1 / Phase 2 |
| Recruiting | A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continua NCT05033691 | Hadassah Medical Organization | N/A |
| Completed | A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor NCT04691388 | Zhejiang Cancer Hospital | Phase 2 |
| Active Not Recruiting | A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC NCT04736823 | Akeso | Phase 2 |
| Active Not Recruiting | Epidemiology of Young Lung Cancer - Survey NCT04640259 | Addario Lung Cancer Medical Institute | — |
| Active Not Recruiting | Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy NCT04716946 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study NCT04672460 | Pfizer | Phase 1 |
| Completed | Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients NCT04552613 | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | N/A |
| Unknown | Dose Tapering and Early Discontinuation to InCreAse cosT-effectIveness Of Immunotherapy for NSCLC NCT04909684 | Radboud University Medical Center | Phase 3 |
| Completed | A Trial of AK104 Plus Anlotinib in NSCLC NCT04646330 | Akeso | Phase 1 / Phase 2 |
| Recruiting | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750 | PMV Pharmaceuticals, Inc | Phase 1 / Phase 2 |
| Completed | Antitumor Activity and Safety of BEBT-109, a Novel EGFR Inhibitor, in Previously Treated NSCLC NCT06001671 | Hunan Province Tumor Hospital | Phase 1 |
| Terminated | Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects Wit NCT04549025 | Jounce Therapeutics, Inc. | Phase 2 |
| Terminated | Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC NCT04476797 | Galera Therapeutics, Inc. | Phase 1 / Phase 2 |
| Terminated | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) NCT04504916 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 2 |
| Unknown | Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study NCT04575415 | Guangdong Association of Clinical Trials | — |
| Active Not Recruiting | Study to Evaluate D-1553 in Subjects With Solid Tumors NCT04585035 | InventisBio Co., Ltd | Phase 1 / Phase 2 |
| Recruiting | A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous NCT04370587 | ImmVira Pharma Co. Ltd | Phase 1 / Phase 2 |
| Unknown | Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer NCT04506242 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies NCT04114136 | Dan Zandberg | Phase 2 |